

Resource Summary Report

Generated by PRECISE-TBI on Aug 31, 2026

MTAP Antibody

RRID:AB_1904054

Type: Antibody

Proper Citation

Cell Signaling Technology Cat# 4158, RRID:AB_1904054

Antibody Information

URL: http://antibodyregistry.org/AB_1904054

Proper Citation: Cell Signaling Technology Cat# 4158, RRID:AB_1904054

Target Antigen: MTAP

Host Organism: rabbit

Clonality: polyclonal

Comments: Applications: W, IP

Antibody Name: MTAP Antibody

Description: This polyclonal targets MTAP

Target Organism: rat, h, m, mouse, r, human, mk

Antibody ID: AB_1904054

Vendor: Cell Signaling Technology

Catalog Number: 4158

Record Creation Time: 20250819T231852+0000

Record Last Update: 20250820T045729+0000

Ratings and Alerts

No rating or validation information has been found for MTAP Antibody.

No alerts have been found for MTAP Antibody.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 6 mentions in open access literature.

Listed below are recent publications. The full list is available at [PRECISE-TBI](#) .

Fu R, et al. (2026) Acquired resistance to the PRMT5 inhibitor confers collateral sensitivity to MEK inhibition in MTAP-null non-small cell lung cancer. bioRxiv : the preprint server for biology.

Fang J, et al. (2025) The context-dependent epigenetic and organogenesis programs determine 3D vs. 2D cellular fitness of MYC-driven murine liver cancer cells. eLife, 14.

Fowler CE, et al. (2025) The PRMT5-splicing axis is a critical oncogenic vulnerability that regulates detained intron splicing. iScience, 28(7), 112965.

Zhang X, et al. (2025) MTA-Cooperative PRMT5 Inhibitors Are Efficacious in MTAP-Deleted Malignant Peripheral Nerve Sheath Tumor Models. Clinical cancer research : an official journal of the American Association for Cancer Research, 31(22), 4779.

Du C, et al. (2019) A PRMT5-RNF168-SMURF2 Axis Controls H2AX Proteostasis. Cell reports, 28(12), 3199.

Fedoriw A, et al. (2019) Anti-tumor Activity of the Type I PRMT Inhibitor, GSK3368715, Synergizes with PRMT5 Inhibition through MTAP Loss. Cancer cell, 36(1), 100.